Pancreatic Islet Cell Transplantation Project, Research Institute National Center for Global Health and Medicine, 1-21-1 Toyama Shinjuku-ku, Tokyo 162-8655, Japan.
Biomaterials Business Division, Mochida Pharmaceutical Co., Ltd., 722 Uenohara, Jimba, Gotemba, Shizuoka 412-8524, Japan.
Cell Rep Methods. 2022 Dec 21;3(1):100370. doi: 10.1016/j.crmeth.2022.100370. eCollection 2023 Jan 23.
Islet transplantation is an effective treatment for type 1 diabetes (T1D). However, a shortage of donors and the need for immunosuppressants are major issues. The ideal solution is to develop a source of insulin-secreting cells and an immunoprotective method. No bioartificial pancreas (BAP) devices currently meet all of the functions of long-term glycemic control, islet survival, immunoprotection, discordant xenotransplantation feasibility, and biocompatibility. We developed a device in which porcine islets were encapsulated in a highly stable and permeable hydrogel and a biocompatible immunoisolation membrane. Discordant xenotransplantation of the device into diabetic mice improved glycemic control for more than 200 days. Glycemic control was also improved in new diabetic mice "relay-transplanted" with the device after its retrieval. The easily retrieved devices exhibited almost no adhesion or fibrosis and showed sustained insulin secretion even after the two xenotransplantations. This device has the potential to be a useful BAP for T1D.
胰岛移植是治疗 1 型糖尿病 (T1D) 的有效方法。然而，供体短缺和需要免疫抑制剂是主要问题。理想的解决方案是开发胰岛素分泌细胞的来源和免疫保护方法。目前没有生物人工胰腺 (BAP) 设备能够满足长期血糖控制、胰岛存活、免疫保护、异种移植可行性和生物相容性的所有功能。我们开发了一种装置，其中猪胰岛被包裹在一种高度稳定和可渗透的水凝胶和一种生物相容的免疫隔离膜中。该装置的异种移植到糖尿病小鼠中，改善了超过 200 天的血糖控制。在取出装置后，对“接力移植”该装置的新糖尿病小鼠，血糖控制也得到了改善。易于取出的装置几乎没有粘连或纤维化，即使经过两次异种移植，也能持续分泌胰岛素。该装置有可能成为治疗 T1D 的有用的 BAP。
